Sutro Biopharma (STRO) Receivables (2017 - 2025)
Historic Receivables for Sutro Biopharma (STRO) over the last 9 years, with Q3 2025 value amounting to $3.9 million.
- Sutro Biopharma's Receivables fell 4106.69% to $3.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.9 million, marking a year-over-year decrease of 4106.69%. This contributed to the annual value of $8.6 million for FY2024, which is 7611.84% down from last year.
- Per Sutro Biopharma's latest filing, its Receivables stood at $3.9 million for Q3 2025, which was down 4106.69% from $8.0 million recorded in Q2 2025.
- Sutro Biopharma's 5-year Receivables high stood at $97.7 million for Q2 2022, and its period low was $3.9 million during Q3 2025.
- Its 5-year average for Receivables is $16.9 million, with a median of $10.0 million in 2023.
- As far as peak fluctuations go, Sutro Biopharma's Receivables soared by 96627.73% in 2022, and later plummeted by 8976.26% in 2023.
- Sutro Biopharma's Receivables (Quarter) stood at $12.5 million in 2021, then tumbled by 42.81% to $7.1 million in 2022, then skyrocketed by 406.57% to $36.1 million in 2023, then plummeted by 76.12% to $8.6 million in 2024, then crashed by 54.48% to $3.9 million in 2025.
- Its Receivables was $3.9 million in Q3 2025, compared to $8.0 million in Q2 2025 and $13.6 million in Q1 2025.